DE69232564D1 - Phospholipide - Google Patents

Phospholipide

Info

Publication number
DE69232564D1
DE69232564D1 DE69232564T DE69232564T DE69232564D1 DE 69232564 D1 DE69232564 D1 DE 69232564D1 DE 69232564 T DE69232564 T DE 69232564T DE 69232564 T DE69232564 T DE 69232564T DE 69232564 D1 DE69232564 D1 DE 69232564D1
Authority
DE
Germany
Prior art keywords
pct
dha
epa
fatty acids
phospholipids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232564T
Other languages
English (en)
Other versions
DE69232564T2 (de
Inventor
Carin Larsson-Backstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi AB
Original Assignee
Fresenius Kabi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi AB filed Critical Fresenius Kabi AB
Application granted granted Critical
Publication of DE69232564D1 publication Critical patent/DE69232564D1/de
Publication of DE69232564T2 publication Critical patent/DE69232564T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/01—Other fatty acid esters, e.g. phosphatides
    • A23D7/011—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
DE69232564T 1991-05-30 1992-05-19 Phospholipide Expired - Fee Related DE69232564T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9101642A SE9101642D0 (sv) 1991-05-30 1991-05-30 Phospholipids
PCT/SE1992/000333 WO1992021335A1 (en) 1991-05-30 1992-05-19 Phospholipids

Publications (2)

Publication Number Publication Date
DE69232564D1 true DE69232564D1 (de) 2002-05-23
DE69232564T2 DE69232564T2 (de) 2002-09-26

Family

ID=20382886

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232564T Expired - Fee Related DE69232564T2 (de) 1991-05-30 1992-05-19 Phospholipide

Country Status (14)

Country Link
US (1) US5434183A (de)
EP (1) EP0660708B1 (de)
JP (1) JP3387498B2 (de)
AT (1) ATE216227T1 (de)
AU (1) AU657969B2 (de)
CA (1) CA2109611A1 (de)
DE (1) DE69232564T2 (de)
ES (1) ES2174833T3 (de)
IE (1) IE921477A1 (de)
NZ (1) NZ242697A (de)
PT (1) PT100524B (de)
SE (1) SE9101642D0 (de)
SG (1) SG64864A1 (de)
WO (1) WO1992021335A1 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
WO1994022313A1 (en) * 1993-04-01 1994-10-13 Ici Australia Operations Proprietary Limited Pan release agent
WO1994028732A1 (en) * 1993-06-07 1994-12-22 Ici Australia Operations Proprietary Limited Reduction of moisture loss from plant and animal matter
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
EP0784437B1 (de) * 1994-10-05 1998-07-08 MILUPA GmbH & Co. KG Phospholipidhaltige fettmischung mit lcp-fettsäuren
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
DK0862369T4 (da) * 1995-11-24 2009-12-14 Unilever Nv Sammensætning baseret på fiskeolie
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
DE19608137A1 (de) * 1996-03-02 1997-09-04 Meyer Lucas Gmbh & Co Lipid-Zubereitungen für diätetische Zwecke
DE19644518A1 (de) * 1996-10-25 1998-04-30 Nutricia Nv Wässrige Fettemulsion, diese enthaltende Nahrung und deren Verwendung
US6852870B2 (en) * 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US6344482B1 (en) * 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US5955102A (en) 1998-09-04 1999-09-21 Amway Corporation Softgel capsule containing DHA and antioxidants
CO5111023A1 (es) 1998-12-31 2001-12-26 Kimberly Clark Co Composicion de articulo absorbente y metodo para usarla para secuestrar irritantes de la piel
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
GB0014437D0 (en) * 2000-06-14 2000-08-09 Porter William L Immune response stimulation
EP1289530B1 (de) * 2000-06-14 2006-10-04 PORTER, William Leslie Lipide zur änderung des abwehrsystems
AU2002241738A1 (en) * 2000-12-29 2002-07-16 The Trustees Of Columbia University In The City Of New York Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds
EP2255668A3 (de) * 2001-05-14 2012-04-04 Martek Biosciences Corporation Herstellung und Verwendung einer an polaren Lipiden reichen Fraktion, die hoch ungesättigte Omega-3- und/oder Omega-6-Fettsäuren aus Mikroben, Samen genetisch modifizierter Pflanzen und marinen Organismen enthält
EP1279400A1 (de) * 2001-07-25 2003-01-29 Target Hit sa Änderung der Fettsäurezusammensetzung Organ- und Gewebe-Zellmembranen
AU2002319961A1 (en) * 2001-07-27 2003-02-17 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
PT1417211E (pt) * 2001-07-27 2007-08-28 Neptune Technologies & Bioress Fosfolípidos naturais de origem marinha contendo flavonóides e fosfolípidos polinsaturados e suas utilizações.
WO2003017945A2 (en) * 2001-08-24 2003-03-06 Martek Biosciences Boulder Corporation Products containing highly unsaturated fatty acids for use by women and their children during stages of preconception, pregnancy and lactation/post-partum
CA2478245A1 (en) * 2002-03-08 2003-09-18 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
AU2003283429A1 (en) * 2002-11-26 2004-06-18 Phares Pharmaceutical Research N.V. Marine lipid compositions
ITMI20030036A1 (it) * 2003-01-13 2004-07-14 Hunza Di Pistolesi Elvira & C S A S Preparazioni farmacologiche o dietetiche costituite da
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US8633247B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
WO2005046669A1 (en) * 2003-11-12 2005-05-26 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (pn)
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
EP1755409B1 (de) * 2004-06-10 2007-10-31 Kellogg Company Lokale applikation von meerölen bei lebensmitteln
US8637495B2 (en) * 2004-07-01 2014-01-28 Nestec S.A. Osteoarthritis diet formulations
WO2006052134A2 (en) * 2004-11-12 2006-05-18 N.V. Nutricia Food composition comprising a protein- and a lipid fraction for rapidly attenuating inflammatory responses
FR2880538B1 (fr) * 2005-01-07 2008-12-26 Polaris Soc Par Actions Simpli Composition cosmetique et cosmeceutique a base d'huiles de poissons, de phospholipides d'origine marine avec ou sans huile de pepins de franboise
GB0506788D0 (en) * 2005-04-04 2005-05-11 Biosea Man As Process
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
JP2009523414A (ja) * 2005-12-21 2009-06-25 ブルーディ、テクノロジー、ソシエダッド、リミターダ 細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用
US20070225370A1 (en) * 2006-03-21 2007-09-27 Joar Opheim Nutritional Compositions and Methods
WO2008149177A2 (en) * 2006-05-05 2008-12-11 Natural Asa Marine lipid compositions and uses thereof
US20080044487A1 (en) 2006-05-05 2008-02-21 Natural Asa Anti-inflammatory properties of marine lipid compositions
US20100048705A1 (en) * 2006-11-09 2010-02-25 Children's Medical Center Corporation Methods of treating and preventing neovascularization with omega-3 polyunsaturated fatty acids
WO2008070467A2 (en) * 2006-12-01 2008-06-12 Joseph Thomas Weishaar Method for preventing chronic disease
US8129432B2 (en) 2007-02-15 2012-03-06 Chu Sainte-Justine Method of correcting imbalance between bone resorption and bone formation and kits and compositions therefor
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
ES2415684T3 (es) 2007-03-28 2013-07-26 Aker Biomarine As Composiciones de aceite de kril biológicamente eficaces
WO2008119170A1 (en) 2007-03-30 2008-10-09 Chu Sainte Justine Method of determining risk of scoliosis
WO2008140026A1 (ja) * 2007-05-11 2008-11-20 Bizen Chemical Co., Ltd. 新規のロイコトリエン受容体アンタゴニスト
KR101192880B1 (ko) * 2007-08-29 2012-10-18 에이커 바이오마린 에이에스에이 새로운 크릴 밀 제조 방법
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
US20090099261A1 (en) * 2007-09-25 2009-04-16 Isi Brands Inc. Omega-3 mixtures
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0808479D0 (en) * 2008-05-09 2008-06-18 Uni I Oslo Topical compositions
JP5924834B2 (ja) 2008-09-02 2016-05-25 アマリン ファーマシューティカルズ アイルランド リミテッド エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
SG173612A1 (en) 2009-02-10 2011-09-29 Amarin Pharma Inc Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
RU2624506C2 (ru) 2009-04-29 2017-07-04 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения
PT2443246T (pt) 2009-06-15 2018-03-14 Amarin Pharmaceuticals Ie Ltd Composições e métodos para reduzir os triglicéridos sem aumentar os níveis de ldl-c num indivíduo em terapia de estatinas concomitante
NO333013B1 (no) 2009-07-06 2013-02-18 Smartfish As Sammensetning omfattende bioaktive aminosyrer eller derivater derav og marin olje i en stabil olje-i-vannemulsjon, og fremgangsmate for fremstilling av nevnte sammensetning.
BR122019016628B8 (pt) 2009-09-23 2021-07-27 Amarin Corp Plc uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
WO2011050474A1 (en) 2009-10-29 2011-05-05 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US8974818B2 (en) * 2010-01-20 2015-03-10 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
PL2720701T3 (pl) * 2011-06-15 2018-01-31 Stable Solutions Llc Terapeutyczne pozajelitowe zastosowanie oleju z kryla
US8895074B2 (en) 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
WO2013033618A1 (en) 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content
EP2775837A4 (de) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Verfahren zur behandlung von hypertriglyceridämie
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
US20150110866A1 (en) * 2012-05-22 2015-04-23 Harold Gordon Cave Complexes and compositions containing curcumin
KR20150036252A (ko) 2012-06-29 2015-04-07 애머린 파마슈티칼스 아일랜드 리미티드 스타틴 요법 중인 대상체에서 심혈관 사건의 위험을 감소시키는 방법
WO2014032183A1 (en) 2012-08-29 2014-03-06 Université Du Québec À Chicoutimi Dihydrochalcone derivatives and their use as antibiotic agents
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
EP3011331B1 (de) 2013-06-17 2019-03-13 CHU Sainte-Justine Gi-proteinphosphorylierung als marker für skoliose und skolioseprogression sowie verfahren zur erhöhung der gipcr-signalisierung bei personen mit skoliose
CA2914213A1 (en) 2013-06-17 2014-12-24 Alain Moreau A method of increasing gipcr signalization in the cells of a scoliotic subject
EP3011332B1 (de) 2013-06-17 2019-09-18 CHU Sainte-Justine Neue marker des schwierigen verlaufs von idiopathischer skoliose und verwendungen davon zur unterteilung von skoliosepatienten und zur vorhersage des risikos der entwicklung von skoliose
EP2826384A1 (de) 2013-07-16 2015-01-21 Evonik Industries AG Verfahren zur Trocknung von Biomasse
WO2015010205A1 (en) 2013-07-22 2015-01-29 Université Du Québec À Chicoutimi Use of plant extracts against herpes simplex virus
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016050552A1 (de) 2014-10-02 2016-04-07 Evonik Degussa Gmbh Verfahren zur herstellung einer pufas enthaltenden biomasse mit hoher zellstabilität
WO2016050556A1 (de) 2014-10-02 2016-04-07 Evonik Degussa Gmbh Verfahren zur anzucht von tieren
ES2873094T3 (es) 2014-10-02 2021-11-03 Evonik Operations Gmbh Procedimiento para la producción de un pienso que contiene PUFAs mediante extrusión de una biomasa que contiene PUFAs de tipo Labyrinthulomycetes
DK180016B1 (da) 2014-10-02 2020-01-22 Evonik Degussa Gmbh Feedstuff of high abrasion resistance and good stability in water, containing PUFAs
BR112017017310B1 (pt) 2015-02-11 2022-07-26 Aker Biomarine Antarctic As Composições lipídicas e suplemento alimentar ou nutricional, alimento médico ou funcional e veículo de liberação oral compreendendo as ditas composições
EP3256003B1 (de) 2015-02-11 2022-11-09 Aker Biomarine Antarctic AS Lipidextraktionsverfahren
US20180051230A1 (en) * 2015-03-19 2018-02-22 Arctic Nutrition As Methods for obtaining phospholipids and compositions thereof
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2018213933A1 (en) 2017-05-25 2018-11-29 The Governors Of The University Of Alberta Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
AU2018313260A1 (en) 2017-08-10 2020-01-16 The Children's Medical Center Corporation Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
SG11202102872QA (en) 2018-09-24 2021-04-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject
CN109527123A (zh) * 2018-12-14 2019-03-29 大连大学 一种对慢性肠炎具有改善作用的调和油
WO2024057117A1 (en) 2022-09-14 2024-03-21 Societe Des Produits Nestle Sa Compositions and methods utilizing southern ocean mackerel oil for providing health benefits in an animal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT333437B (de) * 1974-02-07 1976-11-25 Etapharm Chem Pharm Lab Ges M Verfahren zur herstellung von phosphatidkomplexen mit erhohtem phosphatidylathanolamingehalt aus tierischem material
DE3347269A1 (de) * 1983-12-28 1985-07-11 Pearson & Co (GmbH & Co), 5000 Köln Pharmazeutisch wirksame lecithine mit polyungesaettigten fettsaeuren
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
IT1223290B (it) * 1987-07-27 1990-09-19 Indena Spa Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production

Also Published As

Publication number Publication date
EP0660708A1 (de) 1995-07-05
AU657969B2 (en) 1995-03-30
PT100524B (pt) 1999-08-31
ATE216227T1 (de) 2002-05-15
PT100524A (pt) 1993-08-31
DE69232564T2 (de) 2002-09-26
IE921477A1 (en) 1992-12-02
JP3387498B2 (ja) 2003-03-17
JPH06508123A (ja) 1994-09-14
NZ242697A (en) 1994-02-25
AU1910192A (en) 1993-01-08
CA2109611A1 (en) 1992-12-10
SE9101642D0 (sv) 1991-05-30
SG64864A1 (en) 2001-01-16
EP0660708B1 (de) 2002-04-17
WO1992021335A1 (en) 1992-12-10
US5434183A (en) 1995-07-18
ES2174833T3 (es) 2002-11-16

Similar Documents

Publication Publication Date Title
DE69232564T2 (de) Phospholipide
ES2173673T3 (es) Mezcla grasa y agentes dieteticos o farmaceuticos que las contienen.
US5589508A (en) Use of an emulsion to prepare an intravensously administered medicament for treating skin diseases
KR940018091A (ko) 불포화 지방산을 포함하는 처방
Childs et al. The contrasting effects of a dietary soya lecithin product and corn oil on lipoprotein lipids in normolipidemic and familial hypercholesterolemic subjects
DE3172223D1 (en) Edible, pharmaceutical compositions and processes for making thereof
CA2208817A1 (en) Dietetically balanced milk product
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
KR970704433A (ko) 의약 조성물로서의 DHA의 용도(Use of DHA as a pharmaceutical composition)
DK68080A (da) Anvendelse af fuldstaendigt acetylerede monoglycerider til saenkning af forhoejede cholesterinspejl og eller neutralfedtspejl i menneskeblod
ES2118629T3 (es) Mezcla de grasas conteniendo fosfolipidos con acidos grasos lcp
DE60008127D1 (de) Diät mit hohem lipidgehalt
AU609845B2 (en) Lipid emulsion intended for parenteral or enteral feeding
ATE121592T1 (de) Nicht-temperiertes fett für süsswaren.
ATE33333T1 (de) Diaetetikum.
Carlson The effect of nicotinic acid treatment on the chemical composition of plasma lipoprotein classes in man
DK0456764T3 (da) Omega-3-fedtsyreholdig fedtemulsion til endotracheal indgift, fremstilling og anvendelse heraf
MX172808B (es) Trigliceridos que contienen acidos grasos saturados que tienen de 20 a 24 atomos de carbono utiles para disminuir los niveles de colesterol en la sangre
US4999380A (en) Treatment of lipoprotein disorders associated with cholesterol metabolism
FR2623692B1 (fr) Nouvelle huile dietetique
ES8707111A1 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
CA1314229C (en) Treatment of lipoprotein disorders associated with cholesterol metabolism
Byrne et al. The effects of dietary n‐3 vs. n‐6 fatty acids on ex‐vivo LTB4 generation by canine neutrophils
Brown Structure and metabolism of plasma lipoproteins––an overview
Carlson et al. Effect of coconut oil on plasma apo AI levels in WHHL and NZW rabbits

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee